146 related articles for article (PubMed ID: 34002637)
1. The impact of ligand binding based assays critical reagent characterization and storage.
Haulenbeek J; Beaver CJ
Bioanalysis; 2021 May; 13(10):797-805. PubMed ID: 34002637
[TBL] [Abstract][Full Text] [Related]
2. Critical reagent generation, characterization, handling and storage workflows: impact on ligand binding assays.
Oquendo E; Savoie J; Swenson JM; Grimaldi C
Bioanalysis; 2021 May; 13(10):847-860. PubMed ID: 33890503
[TBL] [Abstract][Full Text] [Related]
3. Critical reagents for ligand-binding assays: process development methodologies to enable high-quality reagents.
Kittinger C; Delmar J; Hewitt L; Holcomb R; Jones C; Jones H; Kubiak R; Lee N; McClenny LC; Mody N; O'Connor E
Bioanalysis; 2022 Feb; 14(3):117-135. PubMed ID: 35019733
[TBL] [Abstract][Full Text] [Related]
4. Adventures in critical reagent lot changes in ligand-binding assays: redevelopment, bridging and additional processing requirements.
Rauwerdink A; Benson M; Jayne A; Babu S; St Charles J; Smith A
Bioanalysis; 2021 May; 13(10):771-777. PubMed ID: 33884890
[No Abstract] [Full Text] [Related]
5. Critical reagent characterization and re-evaluation to ensure long-term stability: two case studies.
Caiazzo TM; Shea CM; Joyce AP
Bioanalysis; 2021 May; 13(10):807-815. PubMed ID: 33884894
[TBL] [Abstract][Full Text] [Related]
6. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.
O'Hara DM; Theobald V; Egan AC; Usansky J; Krishna M; TerWee J; Maia M; Spriggs FP; Kenney J; Safavi A; Keefe J
AAPS J; 2012 Jun; 14(2):316-28. PubMed ID: 22415613
[TBL] [Abstract][Full Text] [Related]
7. Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management.
Geist BJ; Egan AC; Yang TY; Dong Y; Shankar G
Bioanalysis; 2013 Jan; 5(2):227-44. PubMed ID: 23330563
[TBL] [Abstract][Full Text] [Related]
8. Surface plasmon resonance as a tool for ligand-binding assay reagent characterization in bioanalysis of biotherapeutics.
Duo J; Bruno J; Kozhich A; David-Brown D; Luo L; Kwok S; Santockyte R; Haulenbeek J; Liu R; Hamuro L; Peterson JE; Piccoli S; DeSilva B; Pillutla R; Zhang YJ
Bioanalysis; 2018 Apr; 10(8):559-576. PubMed ID: 29701071
[TBL] [Abstract][Full Text] [Related]
9. Critical ligand binding reagent preparation/selection: when specificity depends on reagents.
Rup B; O'Hara D
AAPS J; 2007 May; 9(2):E148-55. PubMed ID: 17614357
[TBL] [Abstract][Full Text] [Related]
10. Life cycle management of critical ligand-binding reagents.
O'Hara DM; Theobald V
Bioanalysis; 2013 Nov; 5(21):2679-96. PubMed ID: 24180507
[TBL] [Abstract][Full Text] [Related]
11. Current and effective strategies for critical reagent characterization, storage, stability, retesting and life cycle management for ligand-binding assays and flow cytometry.
Amaravadi L; Palackal N; Garofolo F
Bioanalysis; 2021 May; 13(10):737-740. PubMed ID: 34037426
[No Abstract] [Full Text] [Related]
12. Critical reagent screening and characterization: benefits and approaches for protein biomarker assays by hybrid LC-MS.
Santockyte R; Zeng J; Zheng N
Bioanalysis; 2019 Apr; 11(8):785-795. PubMed ID: 30994008
[TBL] [Abstract][Full Text] [Related]
13. Quality Controls in Ligand Binding Assays: Recommendations and Best Practices for Preparation, Qualification, Maintenance of Lot to Lot Consistency, and Prevention of Assay Drift.
Azadeh M; Sondag P; Wang Y; Raines M; Sailstad J
AAPS J; 2019 Jul; 21(5):89. PubMed ID: 31297703
[TBL] [Abstract][Full Text] [Related]
14. Critical reagents issues & solutions for anti-drug antibody assays.
Vermet L
Bioanalysis; 2021 May; 13(10):779-786. PubMed ID: 33884895
[No Abstract] [Full Text] [Related]
15. Sponsor relationships, analyte stability in ligand-binding assays and critical reagent management: a bioanalytical CRO perspective.
Lefor Bradford J
Bioanalysis; 2015; 7(11):1337-46. PubMed ID: 26110706
[TBL] [Abstract][Full Text] [Related]
16. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents.
Staack RF; Stracke JO; Stubenrauch K; Vogel R; Schleypen J; Papadimitriou A
Bioanalysis; 2011 Mar; 3(5):523-34. PubMed ID: 21388265
[TBL] [Abstract][Full Text] [Related]
17. Conjugated critical reagent characterization for ligand-binding assays: using MALDI-TOF-MS as an orthogonal tool to assess assay performance.
Haulenbeek J; Piccoli SP
Bioanalysis; 2014 Apr; 6(7):983-92. PubMed ID: 24806906
[TBL] [Abstract][Full Text] [Related]
18. The importance of quality critical reagents for the entire developmental lifecycle of a biopharmaceutical: a pharmacokinetic case study.
Mayer AP; Fraley KJ
Bioanalysis; 2021 May; 13(10):817-827. PubMed ID: 33769084
[No Abstract] [Full Text] [Related]
19. Current Perspectives on Ligand-Binding Assay Practices in the Quantification of Circulating Therapeutic Proteins for Biosimilar Biological Product Development.
Thway TM; Wang YM; Booth BP; Maxfield K; Huang SM; Zineh I
AAPS J; 2019 Dec; 22(1):15. PubMed ID: 31858313
[TBL] [Abstract][Full Text] [Related]
20. Increasing robustness, reliability and storage stability of critical reagents by freeze-drying.
Emrich T; Stracke JO; Guo X; Damhjell K; Moelleken J; Vogel R; Stubenrauch KG; Staack RF
Bioanalysis; 2021 May; 13(10):829-840. PubMed ID: 33890493
[No Abstract] [Full Text] [Related]
[Next] [New Search]
